ClinicalTrials.gg
Active, not recruitingNCT07196748ICONIC-UCUpdated Nov 3, 2026

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

A Phase 3 interventional study of Icotrokinra and Placebo in Colitis, Ulcerative, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 402 sites in 28 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Updated Nov 3, 2026Now Active, not recruitingEnrollment updated+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
896
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies in Colitis, Ulcerative by Johnson & Johnson — 12 open to participants now, 21 under way, 8 of them phase 3. Colitis, Ulcerative · Johnson & Johnson.

Enrollment
5th of 28
896 · median 205
Started
2025
with 3 others
Phase 3
15 of 43
2 open now
Primary completion
2028-01
later than 8 of 20 live
Registered
34th of 43
by date

Among the 43 studies in Colitis, Ulcerative by Johnson & Johnson, this one is the 5th largest by enrollment of the 28 interventional ones that give a count, is one of 4 that started in 2025, is one of 15 in phase 3, reaches primary completion later than 8 of the 20 other live ones, and was the 34th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

12 of the 43 studies in Colitis, Ulcerative by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Colitis, Ulcerative by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this protocol is to evaluate the efficacy (how well it works), safety and tolerability of oral icotrokinra as therapy in adult and adolescent participants with moderately to severely active ulcerative colitis (UC, a chronic disease of the large intestine in which the lining of the colon becomes inflamed and develops tiny open ulcers).

03

Conditions studied

  • Colitis, Ulcerative

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of ulcerative colitis (UC) established at least 12 weeks before screening including both endoscopic evidence and a histopathology report consistent with a diagnosis of UC
  • Moderately to severely active UC, defined as a baseline (Week I-0) modified Mayo score of 5 to 9, inclusive, using the endoscopy subscore obtained during the central review of the screening video endoscopy
  • An endoscopy subscore greater than or equal to (>=) 2 as obtained during central review of the screening video endoscopy
  • Adolescent Participants: body weight must be >= 40 kilograms (kg) at baseline (Week I-0)
  • Adult female participants of and all adolescent female participants must have a negative highly sensitive serum pregnancy test (beta-human chorionic gonadotropin [β-hCG]) at screening and a negative urine pregnancy test at Week I-0 prior to administration of study intervention and agree to further pregnancy tests
  • Demonstrated an inadequate response to, or failure to tolerate conventional therapy but are naïve to advanced therapies (ADT naïve), or inadequate response to (that is, primary or secondary nonresponse) or failure to tolerate advanced therapy defined as biologics and/or advanced oral agents for the treatment of UC (ADT-inadequate responder [IR]) as defined in the protocol

Exclusion criteria

Exclusion Criteria:

  • Participants with current known complications of UC such as fulminant colitis, toxic megacolon, or any other manifestation that might require colonic surgery while enrolled in the study
  • Presence of a stoma
  • Presence or history of a fistula
  • Colonic resection within 24 weeks before baseline or any other intra-abdominal or other major surgery performed within 12 weeks before baseline
  • History of extensive colonic resection (that is, less than [\<] 30 centimeter [cm] of colon remaining) or colonic resection that could impair the use of disease severity assessments (for example Mayo Score) to assess response to study intervention
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
896 participants (actual)

Study arms

  • Experimental
    Double-blind (DB) Induction Study: Icotrokinra

    Adult participants will be randomized to receive icotrokinra daily, orally starting at induction Week 0 (Week I-0). At Week I-12, all participants will be evaluated for clinical response and will enter the Maintenance study.

    Drug: Icotrokinra

  • Placebo comparator
    DB Induction Study: Placebo

    Adult participants will be randomized to receive placebo daily, orally starting at Week I-0. At Week I-12, all participants will be evaluated for clinical response and will enter the Maintenance study.

    Drug: Placebo

  • Experimental
    DB Maintenance Study: Icotrokinra

    Adult participants who are in clinical response to icotrokinra at the end of the Induction study will enter the Maintenance study and be randomized to receive icotrokinra daily, orally starting at maintenance Week 0 (Week M-0) through Week M-40. Participants who are clinical nonresponders to icotrokinra or placebo will also enter the Maintenance study directly and receive icotrokinra daily. After completion of the Maintenance study through Week M-40, eligible participants can participate in a long-term extension (LTE).

    Drug: Icotrokinra

  • Placebo comparator
    DB Maintenance Study: Placebo

    Adult participants who are in clinical response to icotrokinra at the end of the Induction study will enter the Maintenance study and be randomized to receive placebo daily, orally starting at Week M-0 through Week M-40. Participants who are clinical responders to placebo will also enter the Maintenance study directly and continue to receive placebo daily. After completion of the Maintenance study through Week M-40, eligible participants can participate in a LTE.

    Drug: Placebo

  • Experimental
    Open-label (OL) Induction Phase: Icotrokinra

    Adolescent participants will enter the Induction phase and receive icotrokinra daily, orally. At Week I-12 all participants will be evaluated for clinical response and will enter the Maintenance phase.

    Drug: Icotrokinra

  • Experimental
    OL Maintenance Phase: Icotrokinra

    Adolescent participants who are in clinical response to icotrokinra will enter the Maintenance phase at Week M-0 and continue to receive icotrokinra daily, orally up to Week M-40. Participants who are nonresponders to icotrokinra will also enter the Maintenance phase to receive icotrokinra daily. After completion of the Maintenance phase through Week M-40, eligible participants can participate in a LTE.

    Drug: Icotrokinra

Interventions

  • Icotrokinra tablet will be administered orally.

    Also known as: JNJ-77242113

  • DrugPlacebo

    Placebo tablet will be administered orally.

06

What researchers measure

Primary outcomes

  1. Double-blind (DB) Induction Study: Percentage of Adult Participants in Clinical Remission at Week I-12

    Percentage of adult participants in clinical remission at Week I-12 will be reported. Clinical remission is defined as stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1.

    Time frame: At Week I-12

  2. DB Maintenance Study: Percentage of Adult Participants in Clinical Remission at Week M-40

    Percentage of adult participants in clinical remission at Week M-40 will be reported. Clinical remission is defined as stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1.

    Time frame: At Week M-40

  3. Open-Label (OL) Maintenance Phase: Percentage of Adolescent Participants in Clinical Remission at Week M-40

    Percentage of adolescent participants in clinical remission at Week M-40 will be reported. Clinical remission is defined as stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1.

    Time frame: At Week M-40

Secondary outcomes

  1. DB Induction Study: Percentage of Adult Participants in Clinical Response at Week I-12

    Percentage of adult participants in clinical response at Week I-12 will be reported. Clinical response is defined as a decrease from baseline in the modified Mayo score by greater than or equal to (\>=) 30 percent (%) and \>=2 points, with either a \>=1-point decrease from baseline in the rectal bleeding subscore or a rectal bleeding subscore of 0 or 1.

    Time frame: At Week I-12

  2. DB Induction Study: Percentage of Adult Participants with Endoscopic Improvement at Week I-12

    Percentage of adult participants with endoscopic improvement at Week I-12 will be reported. Endoscopic improvement is defined as an endoscopy subscore of 0 or 1.

    Time frame: At Week I-12

  3. DB Induction Study: Percentage of Adult Participants in Symptomatic Remission at Week I-12

    Percentage of adult participants in symptomatic remission at Week I-12 will be reported. Symptomatic remission is defined as a stool frequency subscore of 0 or 1 and a rectal bleeding subscore of 0.

    Time frame: At Week I-12

  4. DB Induction Study: Percentage of Adult Participants with Inflammatory Bowel Disease Questionnaire (IBDQ) Remission at Week I-12

    Percentage of adult participants with IBDQ remission at Week I-12 will be reported. IBDQ remission is defined as an IBDQ total score of \>= 170. The IBDQ is a validated, 32-item, self-reported questionnaire for participants with IBD that will be used to evaluate the disease-specific health related quality of life (HRQoL) across 4 dimensional scores: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Scores range from 32 to 224, with higher scores indicating better outcomes.

    Time frame: At Week I-12

  5. DB Induction Study: Percentage of Adult Participants with Histologic-Endoscopic Mucosal Improvement (HEMI) at Week I-12

    Percentage of adult participants with HEMI at Week I-12 will be reported. HEMI is defined as achieving a combination of histologic improvement and endoscopic improvement. Histologic improvement is defined as neutrophil infiltration in less than (\<) 5% of crypts, no crypt destruction, and no erosions, ulcerations, or granulation tissue according to the Geboes grading system. Endoscopic improvement is defined as an endoscopy sub-score of 0 or 1.

    Time frame: At Week I-12

  6. DB Induction Study: Percentage of Adult Participants with Fatigue Response at Week I-12

    Percentage of adult participants with fatigue response at Week I-12 will be reported. Fatigue response is defined as a \>= 7-point reduction in the patient-reported outcomes measurement information system (PROMIS)-fatigue Short Form (SF)-7a total score from baseline. The PROMIS fatigue SF-7a contains 7 items evaluating fatigue-related symptoms (that is, tiredness, exhaustion, mental tiredness, and lack of energy) and associated impacts on daily activities (that is, activity limitations related to work, self-care, and exercise).

    Time frame: At Week I-12

  7. DB Induction Study: Percentage of Adult Participants in Symptomatic Remission at Week I-4

    Percentage of adult participants in symptomatic remission at Week I-4 will be reported. Symptomatic remission is defined as a stool frequency subscore of 0 or 1 and a rectal bleeding subscore of 0.

    Time frame: At Week I-4

  8. DB Induction Study: Percentage of Adult Participants in Endoscopic Remission at Week I-12

    Percentage of adult participants in endoscopic remission at Week I-12 will be reported. Endoscopic remission is defined as an endoscopy subscore of 0.

    Time frame: At Week I-12

  9. DB Induction Study: Percentage of Adult Participants with No Bowel Urgency at Week I-12

    Percentage of adult participants with no bowel urgency at Week I-12 will be reported using the ulcerative colitis patient-reported outcomes signs and symptoms (UC-PRO/SS). The UC-PRO/SS is a 9-item measure that was developed to standardize the quantification of gastrointestinal (GI) signs and symptoms of UC through direct report from participant ratings. The module includes both bowel signs and symptoms and abdominal symptoms, with a recall period of 24 hours.

    Time frame: At Week I-12

  10. DB Induction Study: Percentage of Adult Participants with No Abdominal Pain at Week I-12

    Percentage of adult participants with no abdominal pain at Week I-12 will be reported using the UC-PRO/SS. The UC-PRO/SS is a 9-item measure that was developed to standardize the quantification of GI signs and symptoms of UC through direct report from participant ratings. The module includes both bowel signs and symptoms and abdominal symptoms, with a recall period of 24 hours.

    Time frame: At Week I-12

  11. DB Induction Study: Percentage of Adult Participants with No Bowel Incontinence at Week I-12

    Percentage of adult participants with no bowel incontinence at Week I-12 will be reported using the UC-PRO/SS. The UC-PRO/SS is a 9-item measure that was developed to standardize the quantification of GI signs and symptoms of UC through direct report from participant ratings. The module includes both bowel signs and symptoms and abdominal symptoms, with a recall period of 24 hours.

    Time frame: At Week I-12

  12. DB Induction Study: Percentage of Adult Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Percentage of adult participants with AEs and SAEs will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the intervention. A SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product, is medically important.

    Time frame: Up to Week I-12

  13. DB Maintenance Study: Percentage of Adult Participants with Endoscopic Improvement at Week M-40

    Percentage of adult participants with endoscopic improvement at Week M-40 will be reported. Endoscopic improvement is defined as an endoscopy subscore of 0 or 1.

    Time frame: At Week M-40

  14. DB Maintenance Study: Percentage of Adult Participants in Symptomatic Remission at Week M-40

    Percentage of adult participants in symptomatic remission at Week M-40 will be reported. Symptomatic remission is defined as a stool frequency subscore of 0 or 1 and a rectal bleeding subscore of 0.

    Time frame: At Week M-40

  15. DB Maintenance Study: Percentage of Adult Participants with 90-day Corticosteroid-free Clinical Remission at Week M-40

    Percentage of adult participants with 90-day corticosteroid-free clinical remission at Week M-40 will be reported. 90-day corticosteroid-free clinical remission is defined as the clinical remission at the visit and not receiving corticosteroids for 90 days prior to the visit.

    Time frame: At Week M-40

  16. DB Maintenance Study: Percentage of Adult Participants with HEMI at Week M-40

    Percentage of adult participants with HEMI at Week M-40 will be reported. HEMI is defined as achieving a combination of histologic improvement and endoscopic improvement. Histologic improvement is defined as neutrophil infiltration in \< 5% of crypts, no crypt destruction, and no erosions, ulcerations, or granulation tissue according to the Geboes grading system. Endoscopic improvement is defined as an endoscopy sub-score of 0 or 1.

    Time frame: At Week M-40

  17. DB Maintenance Study: Percentage of Adult Participants with IBDQ Remission at Week M-40

    Percentage of adult participants with IBDQ remission at Week M-40 will be reported. IBDQ remission is defined as an IBDQ total score of \>= 170. The IBDQ is a validated, 32-item, self-reported questionnaire for participants with IBD that will be used to evaluate the disease-specific HRQoL across 4 dimensional scores: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability). Scores range from 32 to 224, with higher scores indicating better outcomes.

    Time frame: At Week M-40

  18. DB Maintenance Study: Percentage of Adult Participants in Endoscopic Remission at Week M-40

    Percentage of adult participants in endoscopic remission at Week M-40 will be reported. Endoscopic remission is defined as an endoscopy subscore of 0.

    Time frame: At Week M-40

  19. DB Maintenance Study: Percentage of Adult Participants in Clinical Remission at Week M-40 Among the Participants who had Achieved Clinical Remission at Maintenance Baseline

    Percentage of adult participants in clinical remission at Week M-40 among the participants who had achieved clinical remission at maintenance baseline will be reported. Clinical remission is defined as stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1.

    Time frame: At Week M-40

  20. DB Maintenance Study: Percentage of Adult Participants in Histologic-Endoscopic Mucosal Remission at Week M-40

    Percentage of adult participants in histologic-endoscopic mucosal remission at Week M-40 will be reported. Histologic-endoscopic mucosal remission is defined as achieving a combination of histologic remission and endoscopic remission. Histologic remission is defined as the absence of neutrophils from the mucosa (both lamina propria and epithelium), no crypt destruction, and no erosions, ulcerations or granulation tissue according to the Geboes grading system. Endoscopic remission is defined as an endoscopy subscore of 0.

    Time frame: At Week M-40

  21. DB Maintenance Study: Percentage of Adult Participants with Fatigue Response at Week M-40

    Percentage of adult participants with fatigue response at Week M-40 will be reported. Fatigue response is defined as a \>= 7-point reduction in the PROMIS-fatigue SF-7a total score from baseline. The PROMIS fatigue SF-7a contains 7 items evaluating fatigue-related symptoms (that is, tiredness, exhaustion, mental tiredness, and lack of energy) and associated impacts on daily activities (that is, activity limitations related to work, self-care, and exercise).

    Time frame: At Week M-40

  22. DB Maintenance Study: Percentage of Adult Participants with Disease Clearance at Week M-40

    Percentage of adult participants with disease clearance at Week M-40 will be reported. Disease clearance is defined as a composite of symptomatic remission and histologic-endoscopic mucosal remission. Symptomatic remission is defined as a stool frequency subscore of 0 or 1 and a rectal bleeding subscore of 0. Histologic-endoscopic mucosal remission is defined as achieving a combination of histologic remission and endoscopic remission.

    Time frame: At Week M-40

  23. DB Maintenance Study: Percentage of Adult Participants with No Bowel Urgency at Week M-40

    Percentage of adult participants with no bowel urgency at Week M-40 will be reported using the UC-PRO/SS. The UC-PRO/SS is a 9-item measure that was developed to standardize the quantification of GI signs and symptoms of UC through direct report from participant ratings. The module includes both bowel signs and symptoms and abdominal symptoms, with a recall period of 24 hours.

    Time frame: At Week M-40

  24. DB Maintenance Study: Percentage of Adult Participants with No Abdominal Pain at Week M-40

    Percentage of adult participants with no abdominal pain at Week M-40 will be reported using the UC-PRO/SS. The UC-PRO/SS is a 9-item measure that was developed to standardize the quantification of GI signs and symptoms of UC through direct report from participant ratings. The module includes both bowel signs and symptoms and abdominal symptoms, with a recall period of 24 hours.

    Time frame: At Week M-40

  25. DB Maintenance Study: Percentage of Adult Participants with No Bowel Incontinence at Week M-40

    Percentage of adult participants with no bowel incontinence at Week M-40 will be reported using the UC-PRO/SS. The UC-PRO/SS is a 9-item measure that was developed to standardize the quantification of GI signs and symptoms of UC through direct report from participant ratings. The module includes both bowel signs and symptoms and abdominal symptoms, with a recall period of 24 hours.

    Time frame: At Week M-40

  26. DB Maintenance Study: Percentage of Adult Participants with AEs and SAEs

    Percentage of adult participants with AEs and SAEs will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the intervention. A SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product, and is medically important.

    Time frame: Up to Week M-40

  27. OL Induction Phase: Percentage of Adolescent Participants in Clinical Response at Week I-12

    Percentage of adolescent participants in clinical response at Week I-12 will be reported. Clinical response is defined as a decrease from baseline in the modified Mayo score by greater than or equal to (\>=) 30 percent (%) and \>=2 points, with either a \>=1-point decrease from baseline in the rectal bleeding subscore or a rectal bleeding subscore of 0 or 1.

    Time frame: At Week I-12

  28. OL Induction Phase: Percentage of Adolescent Participants in Clinical Remission at Week I-12

    Percentage of adolescent participants in clinical remission at Week I-12 will be reported. Clinical remission is defined as stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1.

    Time frame: At Week I-12

  29. OL Induction Phase: Percentage of Adolescent Participants with HEMI at Week I-12

    Percentage of adolescent participants with HEMI at Week I-12 will be reported. HEMI is defined as achieving a combination of histologic improvement and endoscopic improvement. Histologic improvement is defined as neutrophil infiltration in less than (\<) 5% of crypts, no crypt destruction, and no erosions, ulcerations, or granulation tissue according to the Geboes grading system. Endoscopic improvement is defined as an endoscopy sub-score of 0 or 1.

    Time frame: At Week I-12

  30. OL Induction Phase: Percentage of Adolescent Participants with Endoscopic Improvement at Week I-12

    Percentage of adolescent participants with endoscopic improvement at Week I-12 will be reported. Endoscopic improvement is defined as an endoscopy subscore of 0 or 1.

    Time frame: At Week I-12

  31. OL Induction Phase: Percentage of Adolescent Participants in Symptomatic Remission at Week I-12

    Percentage of adolescent participants in symptomatic remission at Week I-12 will be reported. Symptomatic remission is defined as a stool frequency subscore of 0 or 1 and a rectal bleeding subscore of 0.

    Time frame: At Week I-12

  32. OL Induction Phase: Percentage of Adolescent Participants in Endoscopic Remission at Week I-12

    Percentage of adolescent participants in endoscopic remission at Week I-12 will be reported. Endoscopic remission is defined as an endoscopy subscore of 0.

    Time frame: At Week I-12

  33. OL Induction Phase: Percentage of Adolescent Participants in Pediatric Ulcerative Colitis Activity Index (PUCAI) Remission at Week I-12

    Percentage of adolescent participants in PUCAI remission at Week I-12 will be reported. PUCAI remission is defined as a PUCAI score \<10. The PUCAI is a non-invasive instrument for measuring disease activity in adolescents with UC. Disease activity is determined as a score based on evaluation of abdominal pain, rectal bleeding, stool consistency, number of stools, nocturnal bowel movement, and activity level. The PUCAI score ranges from 0 to 85.

    Time frame: At Week I-12

  34. OL Induction Phase: Percentage of Adolescent Participants with AEs and SAEs

    Percentage of adolescent participants with AEs and SAEs will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the intervention. A SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product, and is medically important.

    Time frame: Up to Week I-12

  35. OL Maintenance Study: Percentage of Adolescent Participants with Endoscopic Improvement at Week M-40

    Percentage of adolescent participants with endoscopic improvement at Week M-40 will be reported. Endoscopic improvement is defined as an endoscopy subscore of 0 or 1.

    Time frame: At Week M-40

  36. OL Maintenance Phase: Percentage of Adolescent Participants in Symptomatic Remission at Week M-40

    Percentage of adolescent participants in symptomatic remission at Week M-40 will be reported. Symptomatic remission is defined as a stool frequency subscore of 0 or 1 and a rectal bleeding subscore of 0.

    Time frame: At Week M-40

  37. OL Maintenance Phase: Percentage of Adolescent Participants in 90-day Corticosteroid-free Clinical Remission at Week M-40

    Percentage of adolescent participants in 90-day corticosteroid-free clinical remission at Week M-40 will be reported. 90-day corticosteroid-free clinical remission is defined as the clinical remission at the visit and not receiving corticosteroids for 90 days prior to the visit.

    Time frame: At Week M-40

  38. OL Maintenance Phase: Percentage of Adolescent Participants with HEMI at Week M-40

    Percentage of adolescent participants with HEMI at Week M-40 will be reported. HEMI is defined as achieving a combination of histologic improvement and endoscopic improvement. Histologic improvement is defined as neutrophil infiltration in \< 5% of crypts, no crypt destruction, and no erosions, ulcerations, or granulation tissue according to the Geboes grading system. Endoscopic improvement is defined as an endoscopy sub-score of 0 or 1.

    Time frame: At Week M-40

  39. OL Maintenance Phase: Percentage of Adolescent Participants with Histologic-Endoscopic Mucosal Remission at Week M-40

    Percentage of adolescent participants with histologic-endoscopic mucosal remission at Week M-40 will be reported. Histologic-endoscopic mucosal remission is defined as achieving a combination of histologic remission and endoscopic remission. Histologic remission is defined as the absence of neutrophils from the mucosa (both lamina propria and epithelium), no crypt destruction, and no erosions, ulcerations or granulation tissue according to the Geboes grading system. Endoscopic remission is defined as an endoscopy subscore of 0.

    Time frame: At Week M-40

  40. OL Maintenance Phase: Percentage of Adolescent Participants with Endoscopic Remission at Week M-40

    Percentage of adolescent participants with endoscopic remission at Week M-40 will be reported. Endoscopic remission is defined as an endoscopy subscore of 0.

    Time frame: At Week M-40

  41. OL Maintenance Phase: Percentage of Adolescent Participants in Clinical Remission at Week M-40 Among the Participants who had Achieved Clinical Remission at Maintenance Baseline

    Percentage of adolescent participants in clinical remission at Week M-40 among the participants who had achieved clinical remission at maintenance baseline will be reported. Clinical remission is defined as stool frequency subscore of 0 or 1, a rectal bleeding subscore of 0, and an endoscopy subscore of 0 or 1.

    Time frame: At Week M-40

  42. OL Maintenance Phase: Percentage of Adolescent Participants in Clinical Response at Week M-40 Among the Participants who had Achieved Clinical Response at Maintenance Baseline

    Percentage of adolescent participants in clinical response at Week M-40 among the participants who had achieved clinical response at maintenance baseline will be reported. Clinical response is defined as a decrease from baseline in the modified Mayo score by \>= 30 % and \>=2 points, with either a \>=1-point decrease from baseline in the rectal bleeding subscore or a rectal bleeding subscore of 0 or 1.

    Time frame: At Week M-40

  43. OL Maintenance Phase: Percentage of Adolescent Participants in PUCAI Remission at Week-40

    Percentage of adolescent participants in PUCAI remission at Week M-40 will be reported. PUCAI remission is defined as a PUCAI score \<10. The PUCAI is a non-invasive instrument for measuring disease activity in adolescents with UC. Disease activity is determined as a score based on evaluation of abdominal pain, rectal bleeding, stool consistency, number of stools, nocturnal bowel movement, and activity level. The PUCAI score ranges from 0 to 85.

    Time frame: At Week M-40

  44. OL Maintenance Phase: Percentage of Adolescent Participants with AEs and SAEs

    Percentage of adolescent participants with AEs and SAEs will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the intervention. A SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product, and is medically important.

    Time frame: Up to Week M-40

07

Study locations

402 sites

Showing the first 100 of 402 sites across 28 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · innovativemedicine.jnj.com

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jan 2028, 27 months after the start.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's planned 27 months is below that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2025
First posted
Sep 29, 2025
StartActual
Oct 1, 2025
Primary completionEst.
Jan 14, 2028
CompletionEst.
Jan 13, 2032
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 3, 2026
Sites
2 sites added, 1 site removed. 5 sites changed recruiting status (5 now completed)
Show 5 sites
  • Toronto Immune and Digestive Health Institute Inc · Toronto, CanadaRecruiting→Completed
  • Studiengesellschaft Mitteldeutschland GmbH · Halle, GermanyRecruiting→Completed
  • Shamir Medical Center Assaf Harofeh 1 · Be’er Ya‘aqov, IsraelRecruiting→Completed
  • Uls Alto Ave - Hosp. Sra. Da Oliveira Guimaraes · Guimarães, PortugalRecruiting→Completed
  • Uls Santo Antonio - Hosp. Santo Antonio · Porto, PortugalRecruiting→Completed
Show 2 added (1 United States, 1 Australia)
  • Stanford Medicine Children's Health · Palo Alto, United States
  • John Hunter Hospital · New Lambton, Australia
Show 1 removed
  • John Hunter Hospital · New Lambton Heights, Australia
across 2 updates, Sep 25, 2026 – Nov 3, 2026
Enrollment
882 (estimated)→896 (actual)
Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    Recruiting→Active, not recruiting
    1 site added, 1 site removed
    Show site
    • John Hunter Hospital · New Lambton, Australia
    Show 1 removed
    • John Hunter Hospital · New Lambton Heights, Australia
    Enrollment 882 (estimated)→896 (actual)
    + 2 other changes: verification date and contact details
  2. Sep 25, 2026
    1 site added. 5 sites changed recruiting status (5 now completed)
    Show 5 sites
    • Toronto Immune and Digestive Health Institute Inc · Toronto, CanadaRecruiting→Completed
    • Studiengesellschaft Mitteldeutschland GmbH · Halle, GermanyRecruiting→Completed
    • Shamir Medical Center Assaf Harofeh 1 · Be’er Ya‘aqov, IsraelRecruiting→Completed
    • Uls Alto Ave - Hosp. Sra. Da Oliveira Guimaraes · Guimarães, PortugalRecruiting→Completed
    • Uls Santo Antonio - Hosp. Santo Antonio · Porto, PortugalRecruiting→Completed
    Show site
    • Stanford Medicine Children's Health · Palo Alto, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07196748
Responsible party
Sponsor
First posted
Sep 29, 2025
Start date
Oct 1, 2025
Primary completion
Jan 14, 2028 (estimated)
Completion
Jan 13, 2032 (estimated)
Last update
Nov 3, 2026

Study contacts

Janssen Research & Development, LLC Clinical trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Icotrokinra

Start the discussion